11:42 AM EST - QLT Inc : announced that the first patient has been dosed in the Company's Phase IIa proof-of-concept trial of QLT091001 in adult subjects with Impaired Dark Adaptation, a condition that results in decreased ability to recover visual sensitivity in the dark after exposure to bright lights. QLT Inc
shares T.QLT are trading unchanged at $6.25.
